PAVmed and Subsidiary Veris Health Complete Private Placement Financing
PAVmed (PAVM) and its subsidiary Veris Health have completed a $2.37 million private placement financing. The deal includes PAVmed securities priced at-the-market and Veris common stock at a $35 million pre-money valuation.
This financing, combined with a recently secured $1.8 million non-dilutive two-year NIH grant, will fund the development of Veris' implantable physiological monitor. The company aims to enhance personalized cancer care through early detection of complications and reduced unplanned hospitalizations.
The financing represents a strategic milestone for Veris Health's commercial strategy, including regulatory clearance and launch of its implantable physiological monitor. Management believes the Veris pre-money valuation demonstrates strong investor confidence in the company's long-term commercial potential.
PAVmed (PAVM) e la sua controllata Veris Health hanno completato un finanziamento di collocamento privato di 2,37 milioni di dollari. L'accordo include titoli PAVmed quotati al mercato e azioni ordinarie Veris a una valutazione pre-money di 35 milioni di dollari.
Questo finanziamento, insieme a un recente grant NIH non diluitivo di 1,8 milioni di dollari ottenuto per due anni, finanzierà lo sviluppo del monitor fisiologico impiantabile di Veris. L'azienda mira a migliorare la cura personalizzata del cancro attraverso la rilevazione precoce delle complicazioni e la riduzione dei ricoveri ospedalieri non pianificati.
Il finanziamento rappresenta una pietra miliare strategica per la strategia commerciale di Veris Health, inclusa l'autorizzazione regolatoria e il lancio del suo monitor fisiologico impiantabile. La direzione ritiene che la valutazione pre-money di Veris dimostri una forte fiducia degli investitori nel potenziale commerciale a lungo termine dell'azienda.
PAVmed (PAVM) y su subsidiaria Veris Health han completado una financiación de colocación privada de 2,37 millones de dólares. El acuerdo incluye valores de PAVmed a precio de mercado y acciones ordinarias de Veris a una valoración pre-money de 35 millones de dólares.
Este financiamiento, combinado con una subvención no dilutiva de 1,8 millones de dólares del NIH asegurada recientemente por dos años, financiará el desarrollo del monitor fisiológico implantable de Veris. La empresa tiene como objetivo mejorar la atención personalizada del cáncer a través de la detección temprana de complicaciones y la reducción de hospitalizaciones no planificadas.
El financiamiento representa un hito estratégico para la estrategia comercial de Veris Health, que incluye la autorización regulatoria y el lanzamiento de su monitor fisiológico implantable. La dirección cree que la valoración pre-money de Veris demuestra una fuerte confianza de los inversores en el potencial comercial a largo plazo de la empresa.
PAVmed (PAVM)와 그 자회사 Veris Health가 237만 달러의 사모 펀딩을 완료했습니다. 이 거래에는 시장 가격으로 책정된 PAVmed 증권과 3천5백만 달러의 사전 평가액으로 Veris의 보통주가 포함됩니다.
이번 자금 조달은 최근 확보한 180만 달러의 비희석 2년 NIH 보조금과 결합되어 Veris의 이식 가능한 생리 모니터 개발에 자금을 지원할 것입니다. 이 회사는 조기 합병증 발견과 계획되지 않은 입원 감소를 통해 개인화된 암 치료를 향상시키는 것을 목표로 하고 있습니다.
이번 자금 조달은 Veris Health의 상업 전략에 있어 전략적 이정표를 나타내며, 여기에는 이식 가능한 생리 모니터의 규제 승인 및 출시가 포함됩니다. 경영진은 Veris의 사전 평가액이 회사의 장기 상업적 잠재력에 대한 강한 투자자 신뢰를 보여준다고 믿고 있습니다.
PAVmed (PAVM) et sa filiale Veris Health ont complété un financement par placement privé de 2,37 millions de dollars. L'accord comprend des titres PAVmed au prix du marché et des actions ordinaires de Veris à une valorisation pré-monétaire de 35 millions de dollars.
Ce financement, combiné à une subvention non dilutive de 1,8 million de dollars du NIH récemment obtenue pour deux ans, financera le développement du moniteur physiologique implantable de Veris. L'entreprise vise à améliorer les soins personnalisés du cancer grâce à une détection précoce des complications et à une réduction des hospitalisations imprévues.
Le financement représente une étape stratégique pour la stratégie commerciale de Veris Health, y compris l'autorisation réglementaire et le lancement de son moniteur physiologique implantable. La direction estime que la valorisation pré-monétaire de Veris démontre une forte confiance des investisseurs dans le potentiel commercial à long terme de l'entreprise.
PAVmed (PAVM) und seine Tochtergesellschaft Veris Health haben eine Privatplatzierungsfinanzierung in Höhe von 2,37 Millionen Dollar abgeschlossen. Der Deal umfasst PAVmed-Wertpapiere zum Marktpreis und Veris-Stammaktien mit einer Pre-Money-Bewertung von 35 Millionen Dollar.
Diese Finanzierung, kombiniert mit einem kürzlich gesicherten 1,8 Millionen Dollar nicht verwässernden NIH-Zuschuss über zwei Jahre, wird die Entwicklung des implantierbaren physiologischen Monitors von Veris finanzieren. Das Unternehmen hat sich zum Ziel gesetzt, die personalisierte Krebsbehandlung durch frühzeitige Erkennung von Komplikationen und Reduzierung ungeplanter Krankenhausaufenthalte zu verbessern.
Die Finanzierung stellt einen strategischen Meilenstein für die kommerzielle Strategie von Veris Health dar, einschließlich der regulatorischen Genehmigung und Markteinführung seines implantierbaren physiologischen Monitors. Das Management ist der Meinung, dass die Pre-Money-Bewertung von Veris das starke Vertrauen der Investoren in das langfristige kommerzielle Potenzial des Unternehmens zeigt.
- Secured $2.37 million through private placement financing
- Obtained $1.8 million non-dilutive NIH grant
- Veris Health valued at $35 million pre-money valuation
- Dilutive financing through private placement
Insights
This dual-track financing package reveals a strategic approach to capital raising in the medical device sector. The
The
However, several critical factors warrant attention:
- The at-market pricing of PAVmed securities indicates current market conditions may not support premium pricing, despite the optimistic Veris valuation
- The financing structure, splitting between PAVmed securities and Veris shares, suggests a strategic move to potentially unlock value through separate valuations of the parent company and subsidiary
- While the NIH grant validates the technology's potential, the two-year timeline implies a measured development path before potential commercialization
The focus on regulatory clearance and commercial launch of the implantable monitor represents a clear milestone-driven approach. Success in this endeavor could significantly enhance both companies' market positions, particularly in the growing field of remote patient monitoring and personalized cancer care. The reduction of unplanned hospitalizations through early detection of complications presents a compelling value proposition for healthcare providers and payers.
Gross proceeds of approximately
"This financing marks an important milestone which will allow Veris Health to advance its commercial strategy, including regulatory clearance and launch of its implantable physiological monitor," said Lishan Aklog, M.D., Chairman and CEO of PAVmed and Executive Chairman of Veris Health. "We believe the Veris pre-money valuation reflects strong investor confidence in Veris' long-term commercial potential as it seeks to enhance personalized cancer care through the early detection of complications and reduced unplanned hospitalizations. We expect that, once cleared and launched, the implantable monitor will significantly enhance this commercial potential."
About Veris Health
Veris Health Inc. is a digital health company whose lead product, the Veris Cancer Care Platform, is a comprehensive digital care platform with remote physiological data collection, symptom reporting, telehealth capability, and electronic health record integration. The platform seeks to offer enhanced personalized cancer care through the early detection of complications, reduced unplanned hospitalizations, the provision of longitudinal trends of physiological and clinical data, data-driven risk management tools, and increased patient and provider satisfaction.
Cancer patients enrolled on the platform receive a VerisBox™ of Veris-branded connected health care devices which transmit physiologic data to the cloud-based clinician portal via an embedded cellular connection. A complementary patient portal enables patients to report symptoms, as well as general health and quality of life parameters, to their cancer care team through the Veris patient smartphone app. The app also allows patients to invite caretakers and family members to follow along on their cancer care journey. Veris is also developing an implantable physiological monitor, designed to be implanted in combination with a vascular access port, which will interface with the Veris Cancer Care Platform. The implantable monitor will further enhance the clinical and commercial value of the platform by providing remote physiologic data independent of patient compliance.
Cancer centers and oncology centers interested in learning more about Veris and the Veris Platform, please visit www.verishealth.com to contact a company representative.
About PAVmed
PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its other subsidiary (in addition to Veris), Lucid Diagnostics, is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths.
For more and for more information about PAVmed, please visit pavmed.com.
For more information about Veris Health, please visit verishealth.com.
Forward-Looking Statements
This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of PAVmed's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed's common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance PAVmed's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed's clinical and preclinical studies; whether and when PAVmed's products are cleared by regulatory authorities; market acceptance of PAVmed's products once cleared and commercialized; PAVmed's ability to raise additional funding as needed; and other competitive developments. These factors are difficult or impossible to predict accurately and many of them are beyond PAVmed's control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect PAVmed's future operations, see Part I, Item 1A, "Risk Factors," in PAVmed's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by PAVmed after its most recent Annual Report. PAVmed disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/pavmed-and-subsidiary-veris-health-complete-private-placement-financing-302383378.html
SOURCE PAVmed Inc.
FAQ
How much funding did PAVmed (PAVM) raise in its February 2025 private placement?
What is the pre-money valuation of Veris Health in PAVmed's 2025 financing?
How will PAVmed (PAVM) use the proceeds from the February 2025 financing?
What additional funding did Veris Health secure besides the private placement?
What is the main product Veris Health is developing with the new funding?
